Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
DarioHealth announced today a new analysis by Sanofi US demonstrating a significant reduction in the cost of care for Dario users compared to non-users living with Type 2 diabetes. The study used an exact match and propensity-score matched non-user cohort that included access to usual care in a cohort of 2,445 Dario users and 7,334 matched non-users. Cost-to-charge ratios were used to determine potential paid savings in costs of care across both inpatient and outpatient care. The study found Dario users incurred a total of $5,077 less in estimated payer charges over the course of a year compared to non-Dario users.
#dtx
#mobile app
Working with a Midwest health plan, Cecelia Health demonstrated a 3.7x return on investment for its virtual diabetes care program within six months of launch. The analysis compared members (including Medicare and Medicaid populations) referred to the Cecelia Health program for those enrolled vs. non-enrolled. Medical claims cost pre- and post- program were analyzed as well as cost savings between the two groups. The outcomes revealed that the program decreased the diabetes claims cost by 38% over six months compared to nonenrolled members, and reduced inpatient costs by 64%.
#virtual care
#telehealth
Lark Health and Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, today announced their expanded partnership where DOHC will offer Lark's Prevention program and CDC-recognized Diabetes Prevention program to their patients. Coming off the success of their Heart Health partnership, DOHC is making Lark's programs available to their greater patient populations for enhanced remote monitoring and scalable education programs designed to improve outcomes and lower total healthcare costs. The new program offerings will enable DOHC to target specific conditions, such as, prediabetes, diabetes, hypertension, high cholesterol and general preventive care.
#insurance
#rpm
#coaching
The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. The researchers tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal insulin. This was a 12-week, multicentre, open-label, parallel, randomised controlled trial conducted in 36 diabetes practices in Germany. Participants in the intervention group titrated their basal insulin dose using a smartphone application (My Dose Coach) for 12 weeks. Control group participants titrated their basal insulin dose according to a written titration chart. The primary outcome was the baseline-adjusted change in HbA1c at 12 weeks. Between 13 July 2021 and 21 March 2022, 251 study participants were randomly assigned and 236 completed the follow-up phase. Study results suggest that utilizing this digital health smartphone application for basal insulin titration may have resulted in a comparatively greater reduction in HbA1c levels among individuals with type 2 diabetes, as compared to basal insulin titration guided by a written titration schedule.
#mobile app
After a challenging year for digital health startups that saw a pullback in funding, could partnerships with pharma companies help fuel success? Felix Lee, Sanofi’s U.S. digital healthcare medical head, said pharmaceutical firms can assist with study design, relationships with insurers, and communicating the benefits of a product to patients. In an interview, Lee talked about why Sanofi decided to partner with DarioHealth, and how bringing a digital health product to market differs from a drug.
#dtx
#bgm
The FDA has cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software for people aged 6 and above with type 1 diabetes. The iLet Bionic Pancreas, which pairs with Dexcom G6 CGM, uses an adaptive, closed-loop algorithm to determine and command insulin delivery, simplifying diabetes management. The system showed promising results in reducing HbA1c and improving the quality of life in trial participants. The company hopes the iLet will alleviate the burden of diabetes management and be a step towards a fully automated insulin dosing system.
#closed loop
#cgm
Abbott's Diabetes business achieved a growth in Q2, generating $1.4 billion in sales, a 19.4% YoY increase. In Diabetes Care, FreeStyle Libre sales were $1.3 billion, which represents sales growth of 22.9 percent on a reported basis and 24.7 percent on an organic basis.
Swimming poses additional challenges for glycemic management with continuous glucose monitoring (CGM) and AID devices. The Omnipod 5 Automated Insulin Delivery System addresses this with a waterproof “Pod”. In the Omnipod 5 pivotal trial, some participants reported continued system function in the water. To investigate in-water system functionality, a single-center observational substudy was conducted from September 2021 until April 2022 among individuals in the Omnipod 5 pivotal extension study at Stanford University. The survey collected information related to swims, including measured interdevice distance and device placement on the body. On-body testing showed that communication success rates dropped off quickly with interdevice distances >13 cm. However, improved connectivity does not fully address glycemic control, which is also influenced by initial glucose at exercise start, circulating insulin levels, carbohydrate intake, and exercise intensity.
#closed loop
#cgm
#insulin pump
The study assessed the effects of continuous glucose monitoring initiation (Dexcom) on emergency department (ED) visits in diabetes patients using insulin. Results from a large health insurer in the southeastern U.S. showed a 14% lower incidence rate of ED visits for CGM initiators compared to non-initiators.
#cgm